Evidence map›Paper›PMID 37126115›Full record

ArticleAnnals of hematology2023

Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics.

Satoshi Yamasaki, Shohei Mizuno, Makoto Iwasaki, Sachiko Seo, Naoyuki Uchida, Miyakoshi Shigesaburo, Nobuaki Nakano, Kazuya Ishiwata, Yasufumi Uehara, Tetsuya Eto and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 1 country.

Satoshi YamasakiDepartment of Internal Medicine, Kyushu University Beppu Hospital, 4546 Tsurumihara, Tsurumi, Beppu, Oita, 874-0838, Japan. yamas009@gmail.com.ORCID http://orcid.org/0000-0002-6143-7906
Shohei MizunoDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.
Makoto IwasakiDepartment of Hematology, Kyoto University Hospital, Kyoto, Japan.
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Mibu, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
Miyakoshi ShigesaburoDepartment of Hematology, Tokyo, Metropolitan Geriatric Hospital, Tokyo, Japan.
Nobuaki NakanoDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Kazuya IshiwataDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Kawasaki, Japan.
Yasufumi UeharaDepartment of Hematology, Kitakyushu City Hospital Organization, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Ken TakaseDepartment of Hematology, National Hospital Organization Kyusyu Medical Center, Fukuoka, Japan.
Toshiro KawakitaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Yuta KatayamaDepartment of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Yuichiro NawaDepartment of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Onizuka MakotoDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
Tatsuo IchinoheDepartment of Hematology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yoshiko AtsutaDepartment of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.
Junya KandaDepartment of Hematology, Kyoto University Hospital, Kyoto, Japan.
Masamitsu YanadaDepartment of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
Aichi Medical University · JPKyoto University Hospital · JPToranomon Hospital · JPAichi Cancer Center · JPAnjo Kosei Hospital · JPDokkyo Medical University · JPEhime Prefectural Central Hospital · JPHamanomachi Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPHiroshima University · JPImamura Hospital · JPKanagawa Prefectural Hospital Organization · JPKitakyushu Municipal Medical Center · JPKumamoto Medical Center · JPKyushu University Beppu Hospital · JPNational Hospital Organization · JPTokai University · JPTokyo Metropolitan Geriatric Hospital · JP

Funding

JSPS KAKENHI 22K12887
6 · The paper itself

Abstract

Unrelated donor bone marrow transplantation (UR-BMT), unrelated donor cord blood stem cell transplantation (UR-CBT), and haploidentical peripheral blood stem cell transplantation (Haplo-PBSCT) are the main alternative stem cell sources for allogeneic hematopoietic cell transplantation (HCT) in Japan. The present study aimed to identify factors associated with the outcomes of UR-BMT, UR-CBT, and Haplo-PBSCT in older patients with acute myeloid leukemia (AML) and intermediate- or poor-risk cytogenetics to improve the clinical efficacy and safety of allogeneic HCT. We retrospectively analyzed data for 448 AML patients aged > 65 years who received UR-BMT (n = 102), UR-CBT (n = 250), or Haplo-PBSCT (n = 96) between 2014 and 2020. Overall survival (OS) in the UR-BMT group was superior (P = 0.033) to that in the other groups. However, all patients without complete remission (non-CR) who had Karnofsky performance status (KPS) < 80 at HCT and poor-risk cytogenetics died within 1 year after HCT. Multivariate Cox regression analysis identified KPS <80 at HCT and poor-risk cytogenetics as independent predictors of worse OS in non-CR patients. KPS < 80 may be an alternative indicator for non-CR AML patients with poor-risk cytogenetics during the selection of HCT, alternative treatments, or best supportive therapy, and the optimal KPS is important for the success of HCT.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAgedBone Marrow TransplantationCytogenetic AnalysisHumansRetrospective StudiesTransplantation ConditioningAcute myeloid leukemiaBone marrow transplantationCord blood stem cell transplantationOlderPeripheral blood stem cell transplantation

Identifiers

PMID37126115
OpenAlexW4367601356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.